SCHEMBL320659

SCHEMBL320659

CC(C)(C)OC(=O)CCN1CCc2oc(-c3ccc(OCc4ccccc4F)cc3)cc2C1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
S1PR5 Q9H228 11/20 0.79
S1PR1 P21453 6/20 0.79
S1PR3 Q99500 5/20 0.79
PDCD1 Q15116 1/20 0.40
CD274 Q9NZQ7 1/20 0.40
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
BTK Q06187 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KCNH2 Q12809 1/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SCN3A Q9NY46 1/20 0.38
MAOB P27338 1/20 0.38
PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15153928 0.95 S1PR5 (0.79) S1PR5S1PR1S1PR3BCHEACHE
SCHEMBL322452 0.88 S1PR5 (1.00) S1PR5S1PR1S1PR3CD274BCHE
SCHEMBL320988 0.85 S1PR5 (1.00) S1PR5S1PR1S1PR3BCHEACHE
SCHEMBL322179 0.83 S1PR5 (0.52) S1PR5S1PR1S1PR3BCHEACHE
SCHEMBL321323 0.81 S1PR5 (0.49) S1PR5S1PR1S1PR3
SCHEMBL321600 0.78 S1PR5 (0.52) S1PR5S1PR1S1PR3PDCD1CD274
SCHEMBL321077 0.78 S1PR5 (0.54) S1PR5S1PR1S1PR3BCHEACHE
SCHEMBL18550449 0.77 S1PR5 (0.52) S1PR5S1PR1S1PR3PDCD1CD274
SCHEMBL320868 0.76 S1PR5 (0.88) S1PR5S1PR1S1PR3CD274MAOB
SCHEMBL321254 0.76 S1PR5 (0.51) S1PR5S1PR1S1PR3BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48301-E1 Fused heterocyclic derivatives as S1P modulators ABBVIE B.V. (NL) 2020-11-10 US disclosed
EP-2590980-B1 FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS ABBVIE BV (NL) 2017-09-20 EP disclosed
US-9670220-B2 Fused heterocyclic derivatives as S1P modulators ABBVIE B.V. (NL) 2017-06-06 US disclosed
US-20150284403-A1 FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS AbbVie Deutschland GmbH & Co. KG (DE) 2015-10-08 US disclosed
US-9096612-B2 Fused heterocyclic derivatives as S1P modulators ABBVIE B.V. (NL) 2015-08-04 US disclosed
US-8796262-B2 Fused heterocyclic derivatives as S1P modulators ABBVIE B.V. (NL) 2014-08-05 US disclosed
US-20140066433-A1 FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS ABBVIE INC (US) 2014-03-06 US disclosed
US-20130203737-A1 FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS ABBVIE B.V. (NL) 2013-08-08 US disclosed
EP-2590980-A1 FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS ABBVIE B.V. (NL) 2013-05-15 EP disclosed
WO-2012004373-A1 FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066433-A1 FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS S1PR5, S1PR1, S1PR3 S1PR5 1/4885S1PR1 2/4885S1PR3 3/4885
US-20130203737-A1 FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS S1PR3, S1PR1, S1PR2 S1PR5 5/4885S1PR1 2/4885S1PR3 1/4885
US-20150284403-A1 FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS S1PR5, S1PR1, S1PR3 S1PR5 1/4885S1PR1 2/4885S1PR3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.